

At page 8, line 5, delete "positions 1 to 331", and insert therefor --positions 2 to 331--.

At page 21, lines 24-25, delete "Pro-75 to about Gly-100", and replace therefor -- Ala-75 to about Arg-100)--;

line 26, delete "Thr-168 to about Leu -180", and replace therefor -- Leu-168 to about Ala-180)--;

line 27, delete "Asp-204 to about Ile-226", and replace therefor -- Thr-204 to about Tyr-226)--;

line 28, delete "Ile-258 to about Pro-281", and replace therefor -- Leu-258 to about Ser-281)--; and

line 29, delete "Glu-291 to about Ser-327", and replace therefor -- Gly-291 to about Pro-327)--.

Please replace pages 44-55 with the enclosed pages 44-54 which contain a replacement sequence listing. Please renumber pages 56-61 as 55-60, respectively.

In the Claims

Please cancel claims 1-20 without prejudice.

Please add the following new claims:

--21. An isolated polypeptide comprising an amino acid sequence which is at least 95% identical to a member selected from the group consisting of:

(a) amino acids 1 to 331 of SEQ ID NO:2 or the complete amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 97343;

(b) amino acids 2 to 331 of SEQ ID NO:2 or the complete amino acid sequence excepting the N-terminal methionine encoded by the cDNA clone contained in ATCC Deposit No. 97343;

(c) amino acids 24 to 331 of SEQ ID NO:2;

(d) amino acids 27 to 331 of SEQ ID NO:2;

(e) amino acids 284 to 330 of SEQ ID NO:2; and

(f) the amino acid sequence of the mature form of Neuronal Attachment Factor-1 (NAF-1) encoded by the cDNA clone contained in ATCC Deposit No. 97343;

subC
cont

wherein percentage of identity is determined using the Bestfit program with parameters set such that the percentage of identity is calculated over the full length of the reference sequence and gaps of up to 5% of the total number of residues in the reference sequence are allowed, and wherein up to 5% of the amino acid residues in the reference sequence may be deleted or substituted with another amino acid, or a number of amino acids up to 5% of the total amino acid residues in the reference sequence may be inserted into the reference sequence.

22. The isolated polypeptide of claim 21 wherein said member is (a).

23. The isolated polypeptide of claim 21 wherein said member is (b).

24. The isolated polypeptide of claim 21 wherein said member is (c).

25. The isolated polypeptide of claim 21 wherein said member is (d).

26. The isolated polypeptide of claim 21 wherein said member is (e).

27. The isolated polypeptide of claim 21 wherein said member is (f).

subC
cont

28. The isolated polypeptide of claim 21, wherein said polypeptide comprises the amino acid sequence of amino acids 1 to 331 of SEQ ID NO:2.

29. The isolated polypeptide of claim 21 wherein said polypeptide comprises the complete amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 97343.

30. The isolated polypeptide of claim 21 wherein said polypeptide comprises the amino acid sequence of amino acids 2 to 331 of SEQ ID NO:2.

31. The isolated polypeptide of claim 21 wherein said polypeptide comprises the complete amino acid sequence excepting the N-terminal methionine encoded by the cDNA clone contained in ATCC Deposit No. 97343.

32. The isolated polypeptide of claim 21 wherein said polypeptide comprises the amino acid sequence of amino acids 24 to 331 of SEQ ID NO:2.

33. The isolated polypeptide of claim 21 wherein said polypeptide comprises the amino acid sequence of amino acids 27 to 331 of SEQ ID NO:2.

34. The isolated polypeptide of claim 21 wherein said polypeptide comprises the amino acid sequence of amino acids 284 to 330 of SEQ ID NO:2.

35. The isolated polypeptide of claim 21, wherein said polypeptide comprises the amino acid sequence of the mature form of NAF-1 encoded by the cDNA clone contained in ATCC Deposit No. 97343.

36. An epitope-bearing portion of the NAF-1 polypeptide comprising at least 7 contiguous amino acids of SEQ ID NO:2.

37. The epitope-bearing portion of claim 36, which comprises at least 9 contiguous amino acids of SEQ ID NO:2.

38. The epitope-bearing portion of claim 36, which comprises amino acids from about 75 to about 100 of SEQ ID NO:2.

39. The epitope-bearing portion of claim 36, which comprises amino acids from about 168 to about 180 of SEQ ID NO:2.

40. The epitope-bearing portion of claim 36, which comprises amino acids from about 204 to about 226 of SEQ ID NO:2.

41. The epitope-bearing portion of claim 36, which comprises amino acids from about 258 to about 281 of SEQ ID NO:2.

42. The epitope-bearing portion of claim 36, which comprises amino acids from about 291 to about 327 of SEQ ID NO:2.

43. An isolated polypeptide comprising at least 10 contiguous amino acids of SEQ ID NO:2.

44. The isolated polypeptide of claim 43, which has at least one activity selected from:

- (a) promotes axonal neurite extension;
- (b) promotes neural cell adhesion; or
- (b) binds to an antibody specific to the polypeptide of SEQ ID NO:2.

45. The isolated polypeptide of claim 44, which promotes axonal neurite extension.

46. The isolated polypeptide of claim 44, which promotes neural cell adhesion.

47. The isolated polypeptide of claim 44, which binds to an antibody specific to the polypeptide of SEQ ID NO:2.

48. The isolated polypeptide of claim 43, which comprises at least 30 contiguous amino acids of SEQ ID NO:2.

49. The isolated polypeptide of claim 43, which comprises at least 50 contiguous amino acids of SEQ ID NO:2.

50. An isolated polypeptide encoded by a polynucleotide that hybridizes under stringent hybridization conditions to the polynucleotide of SEQ ID NO:1 or complement thereof; wherein, said polypeptide has at least one activity selected from:

- (a) promotes axonal neurite extension;
- (b) promotes neural cell adhesion; or
- (b) binds to an antibody specific to the polypeptide of SEQ ID NO:2.

51. The isolated polypeptide of claim 50, which promotes axonal neurite extension.

52. The isolated polypeptide of claim 50, which promotes neural cell adhesion.

53. The isolated polypeptide of claim 50, which binds to an antibody specific to the polypeptide of SEQ ID NO:2.

54. A fusion protein comprising the isolated polypeptide of claim 21 fused to a heterologous polypeptide.

55. A fusion protein comprising the isolated polypeptide of claim 36 fused to a heterologous polypeptide.

56. A fusion protein comprising the isolated polypeptide of claim 43 fused to a heterologous polypeptide.

57. A fusion protein comprising the isolated polypeptide of claim 50 fused to a heterologous polypeptide.

58. A pharmaceutical composition comprising the polypeptide of claim 21 and a pharmaceutically acceptable carrier.